Last reviewed · How we verify
pre-implementation baseline including opioid
Buprenorphine is a partial opioid agonist that works by activating opioid receptors in the brain, reducing the craving for opioids and alleviating withdrawal symptoms.
Buprenorphine is a partial opioid agonist that works by activating opioid receptors in the brain, reducing the craving for opioids and alleviating withdrawal symptoms. Used for Treatment of opioid use disorder, Maintenance therapy for opioid dependence.
At a glance
| Generic name | pre-implementation baseline including opioid |
|---|---|
| Sponsor | Brigham and Women's Hospital |
| Drug class | Opioid partial agonist |
| Target | mu-opioid receptor |
| Modality | Small molecule |
| Therapeutic area | Addiction |
| Phase | Phase 3 |
Mechanism of action
Buprenorphine's partial agonist activity at the mu-opioid receptor reduces the risk of overdose and dependence compared to full opioid agonists. It also has a ceiling effect, limiting the maximum effect on opioid receptors, which helps to prevent excessive sedation and respiratory depression.
Approved indications
- Treatment of opioid use disorder
- Maintenance therapy for opioid dependence
Common side effects
- Nausea
- Headache
- Dizziness
- Sleep disturbances
- Constipation
- Vomiting
- Fatigue
- Insomnia
- Abdominal pain
- Muscle pain
Key clinical trials
- A Bundled Intervention - Phase 2 (PHASE4)
- Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES) (PHASE3)
- ENhanced Recovery in CHildren Undergoing Surgery (PHASE3)
- Opioid Reduction Strategy South Western Ontario (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: